Healing & Recovery

Body Protection Compound-157, Bepecin, PL 14736, PLD-116

A synthetic pentadecapeptide whose sequence derives from a protein found in human gastric juice, studied almost entirely in animal models for tissue repair, tendon and ligament healing, gastrointestinal protection, and angiogenesis. It is not approved for human use, and rigorous human trial data are essentially absent.

AEDL, Ala-Glu-Asp-Leu, H-Ala-Glu-Asp-Leu-OH, Bronchogen (Khavinson bronchial bioregulator), lung peptide bioregulator

A synthetic short tetrapeptide from Vladimir Khavinson's "peptide bioregulator" (cytogen) family, marketed toward bronchial/respiratory tissue research. It has no published human clinical trials, is sold only as a research reagent, and is not an approved medicine anywhere confirmed in the sources found. Not approved for human use.

AEDR, Ala-Glu-Asp-Arg, H-Ala-Glu-Asp-Arg-OH, Cardiogen peptide

A synthetic tetrapeptide (Ala-Glu-Asp-Arg, "AEDR") from the Khavinson school of short "peptide bioregulators," marketed as a heart/myocardium-targeted compound. Its chemistry is verifiable, but supporting evidence is limited to in-vitro binding assays and a hypothesis-level gene-regulation model; cardiac-efficacy claims are unverified and there is no confirmed human data. Not approved for human use anywhere.

AED, Ala-Glu-Asp, L-Alanyl-L-glutamyl-L-aspartic acid, Alanyl-glutamyl-aspartic acid, H-Ala-Glu-Asp-OH, T-31 peptide, PubChem CID 87815447

A synthetic tripeptide (Ala-Glu-Asp, "AED") from Vladimir Khavinson's "short peptide bioregulator" school, marketed toward cartilage and connective-tissue "repair." The verifiable evidence is thin, old and preclinical — a single in-vitro gene-expression study, no animal joint-disease trial and no human data. Not approved for human use.

EDG, Glu-Asp-Gly tripeptide, T-34 tripeptide, Glutamyl-aspartyl-glycine, H-Glu-Asp-Gly-OH, Lung/bronchial mucosa bioregulator

A synthetic tripeptide, Glu-Asp-Gly (EDG), from Vladimir Khavinson's "short peptide bioregulator" school, marketed for bronchial/lung tissue support. Chemistry is well-defined (PubChem CID 194641; CAS 75007-24-8; C11H17N3O8; MW 319.27), but the biological evidence is thin — one in-vitro study plus uncontrolled, unreplicated Russian clinical claims. Not approved for human use.

Lys-Pro-Val, α-MSH(11-13), KPV tripeptide

A tripeptide corresponding to the C-terminal sequence of α-MSH (residues 11–13), studied in vitro and in animal models for anti-inflammatory activity in intestinal and dermal inflammation. Not approved for human use.

EDL peptide, Glu-Asp-Leu, Glutamyl-aspartyl-leucine, L-Glutamyl-L-aspartyl-L-leucine, Ovagen bioregulator

A synthetic tripeptide (Glu-Asp-Leu, "EDL") from the Khavinson "short peptide bioregulator" school, marketed for liver, gastrointestinal-mucosal and immune "support" via a proposed peptide–gene-expression mechanism. The chemistry is verifiable in PubChem, but the biological evidence is limited, older, largely Russian and preclinical, with no verifiable human trials. Not approved for human use.

TB500, Thymosin beta-4 fragment (17-23), Ac-LKKTETQ, Thymosin β4 actin-binding fragment

A synthetic peptide marketed as a fragment of thymosin beta-4 (Tβ4). Analytical work identifies the material sold as "TB-500" as the N-terminal acetylated 17–23 fragment of Tβ4 (Ac-LKKTETQ), the protein's actin-binding motif. Most biological evidence describes full-length Tβ4 in animals and cell culture, not the TB-500 fragment, and there are no human clinical trials of TB-500 itself. It is not approved for human use and is prohibited in sport.

Tβ4, TB4, RGN-259, RGN-352

A naturally occurring 43-amino-acid actin-sequestering peptide that is among the most abundant intracellular peptides in mammalian cells, with studied roles in cell migration, angiogenesis, wound healing, and corneal and cardiac repair. It has been developed as the investigational drug candidates RGN-259 (ophthalmic) and RGN-352 (systemic injectable) in small, early-stage human trials, none of which has yielded an approved product. It is distinct from the marketed fragment TB-500 (Ac-LKKTETQ) and is prohibited in sport.